Leiomyosarcoma of the corpus uteri
diseaseOn this page
Also known as body of uterus leiomyosarcomacorpus uteri leiomyosarcomaleiomyosarcoma - uterusleiomyosarcoma of body of uterusleiomyosarcoma of corpus uterileiomyosarcoma of the body of uterusleiomyosarcoma of the uterine bodyleiomyosarcoma of the uterine corpusleiomyosarcoma of the uterusleiomyosarcoma of uterine bodyleiomyosarcoma of uterine corpusleiomyosarcoma of uterusuterine body leiomyosarcomauterine corpus leiomyosarcomaUterine Leiomyosarcoma
Summary
Leiomyosarcoma of the corpus uteri (MONDO:0016262) is a disease and 29 clinical trials. Molecularly, PTEN Deletion AND BRCA2 Deletion AND TP53 Deletion confers sensitivity to Olaparib in Uterine Leiomyosarcoma (CIViC Level C). Top therapeutic interventions include filgrastim, pegfilgrastim, and trabectedin. A subtype of mixed endometrial stromal and smooth muscle tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 29
- Precision-medicine evidence (CIViC): 1 subtype–drug association
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | leiomyosarcoma of the corpus uteri |
| Mondo ID | MONDO:0016262 |
| EFO | EFO:1001974 |
| Orphanet | 213625 |
| DOID | DOID:5289 |
| NCIT | C6340 |
| SNOMED CT | 447389009 |
| UMLS | C0280631 |
| MedGen | 83679 |
| GARD | 0020477 |
| NORD | 1817 |
| Anatomy (UBERON) | UBERON:0009853 |
| Is cancer (heuristic) | no |
Also known as: body of uterus leiomyosarcoma · corpus uteri leiomyosarcoma · leiomyosarcoma - uterus · leiomyosarcoma of body of uterus · leiomyosarcoma of corpus uteri · leiomyosarcoma of the body of uterus · leiomyosarcoma of the corpus uteri · leiomyosarcoma of the uterine body · leiomyosarcoma of the uterine corpus · leiomyosarcoma of the uterus · leiomyosarcoma of uterine body · leiomyosarcoma of uterine corpus · leiomyosarcoma of uterus · uterine body leiomyosarcoma · uterine corpus leiomyosarcoma · Uterine Leiomyosarcoma · uterine leiomyosarcoma
Data availability: 4 cell lines.
Disease family
This is a subtype of mixed endometrial stromal and smooth muscle tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › connective and soft tissue neoplasm › soft tissue neoplasm › mixed endometrial stromal and smooth muscle tumor › leiomyosarcoma of the corpus uteri
Related subtypes (3): endometrial stromal nodule, uterine corpus perivascular epithelioid cell tumor, uterine corpus rhabdomyosarcoma
Subtypes (2): uterine corpus epithelioid leiomyosarcoma, uterine corpus myxoid leiomyosarcoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 29.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 18 |
| Not specified | 7 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05432791 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working |
| NCT01012297 | PHASE3 | TERMINATED | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma |
| NCT01533207 | PHASE3 | TERMINATED | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery |
| NCT03880019 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma |
| NCT04200443 | PHASE2 | ACTIVE_NOT_RECRUITING | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma |
| NCT04727242 | PHASE2 | ACTIVE_NOT_RECRUITING | CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma |
| NCT05649956 | PHASE2 | RECRUITING | Letrozole in Uterine Leiomyosarcoma |
| NCT06524583 | PHASE2 | RECRUITING | Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour |
| NCT07076186 | PHASE2 | RECRUITING | Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS |
| NCT07467772 | PHASE2 | RECRUITING | Ph 2 Elacestrant in ER Positive Uterine Sarcomas |
| NCT00025220 | PHASE2 | COMPLETED | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus |
| NCT00031629 | PHASE2 | COMPLETED | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus |
| NCT00245102 | PHASE2 | COMPLETED | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma |
| NCT00378911 | PHASE2 | COMPLETED | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus |
| NCT00390234 | PHASE2 | COMPLETED | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma |
| NCT00659360 | PHASE2 | COMPLETED | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma |
| NCT01220609 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy |
| NCT01637961 | PHASE2 | COMPLETED | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus |
| NCT02378142 | PHASE2 | WITHDRAWN | Pazopanib for Treating Uterine Leiomyosarcoma |
| NCT02428192 | PHASE2 | COMPLETED | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma |
| NCT02601209 | PHASE1/PHASE2 | TERMINATED | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma |
| NCT03926936 | PHASE2 | COMPLETED | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study |
| NCT01793168 | Not specified | RECRUITING | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford |
| NCT06244251 | Not specified | ACTIVE_NOT_RECRUITING | Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids |
| NCT00614835 | Not specified | COMPLETED | Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus |
| NCT00897442 | Not specified | COMPLETED | Collecting Tumor Samples From Patients With Gynecological Tumors |
| NCT01958580 | Not specified | TERMINATED | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery |
| NCT04935333 | Not specified | UNKNOWN | Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy |
| NCT06678763 | Not specified | COMPLETED | Combined CRS With HIPEC in Women With Inadvertently Morcellated uLMS |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FILGRASTIM | 4 | 3 |
| PEGFILGRASTIM | 4 | 3 |
| TRABECTEDIN | 4 | 3 |
| GEMCITABINE | 4 | 2 |
| PAZOPANIB | 4 | 2 |
| ELACESTRANT | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| OLAPARIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| TEMOZOLOMIDE | 4 | 1 |
| ALISERTIB | 3 | 1 |
| SARACATINIB | 3 | 1 |
| GADOLINIUM | 2 | 1 |
| SAPANISERTIB | 2 | 1 |
| CHEMBL4068768 | 0 | 1 |
| CHEMBL4171277 | 0 | 1 |
| CHEMBL4228794 | 0 | 1 |
| CHEMBL4248195 | 0 | 1 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL4438584 | 0 | 1 |
| CHEMBL3962632 | 0 | 1 |
| CHEMBL3991933 | 0 | 1 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| EXELIXIS | 0 | 1 |
Precision-medicine subtype map (CIViC)
Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.
| Molecular subtype | Therapy | Effect | Level | CIViC |
|---|---|---|---|---|
| PTEN Deletion AND BRCA2 Deletion AND TP53 Deletion | Olaparib | Sensitivity/Response | CIViC C | EID11319 |